Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.

Abstract

AIM:

To investigate the association between NSUN2/IGF-II signature and ovarian cancer survival.

METHODS:

Using a publicly accessible dataset of RNA sequencing and clinical follow-up data, we performed Classification and Regression Tree and survival analyses.

RESULTS:

Patients with NSUN2 high IGF-II low had significantly superior overall and disease progression-free survival, followed by NSUN2 low IGF-II low, NSUN2 high IGF-II high and NSUN2 low IGF-II high (p < 0.0001 for overall, p = 0.0024 for progression-free survival, respectively). The associations of NSUN2/IGF-II signature with the risks of death and relapse remained significant in multivariate Cox regression models. Random-effects meta-analyses show the upregulated NSUN2 and IGF-II expression in ovarian cancer versus normal tissues.

CONCLUSION:

The NSUN2/IGF-II signature associates with heterogeneous outcome and may have clinical implications in managing ovarian cancer.

• Authors: Jia-Cheng Yang, Eric Risch, Meiqin Zhang, Chan Huang, Huatian Huang, Lingeng Lu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 13 Issue 22 Pg. 1981-1990 (Sep 2017) ISSN: 1744-8301 [Electronic] England
• PMID: 28829218 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• IGF2 protein, human
• Insulin-Like Growth Factor II
• Methyltransferases
• NSUN2 protein, human

Topics

• Adenocarcinoma, Clear Cell (genetics, mortality, pathology)
• Adenocarcinoma, Mucinous (genetics, mortality, pathology)
• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (genetics)
• Cystadenocarcinoma, Serous (genetics, mortality, pathology)
• Endometrial Neoplasms (genetics, mortality, pathology)
• Female
• Follow-Up Studies
• Humans
• Insulin-Like Growth Factor II (genetics)
• Methyltransferases (genetics)
• Middle Aged
• Neoplasm Recurrence, Local (genetics, mortality, pathology)
• Ovarian Neoplasms (genetics, mortality, pathology)
• Prognosis
• Survival Rate